Faster, Smarter TB Resistance Testing: Evaluating Akonni’s XDR-LFC Assay for Multiple Drug Resistance
1. Introduction
Tuberculosis (TB), especially drug-resistant forms, remains a global health challenge—yet universal drug susceptibility testing is still out of reach in many regions. In a prospective study of 566 participants, researchers assessed Akonni’s XDR‑LFC assay for its ability to detect resistance to multiple TB drugs directly from sputum samples—showing promising results for near-patient diagnostics.
2. Background & Relevance
Current molecular diagnostics for TB resistance often focus on only one or two drugs (e.g., rifampin via Xpert MTB/RIF). Akonni’s XDR‑LFC assay broadens this scope by testing resistance across six key anti-TB drugs in a single, rapid test. That makes it a powerful tool for labs looking to expand testing capacity with minimal infrastructure changes.
3. Key Findings
-
Isoniazid: Sensitivity and specificity both 100%.
-
Rifampin: Sensitivity 99.2%, specificity 97.9%.
-
Fluoroquinolones: Sensitivity 84.8%, specificity 99.1%.
-
Kanamycin: Sensitivity 87.0%, specificity 84.1%.
-
Capreomycin: Sensitivity 54.3%, specificity 100%.
-
Amikacin: Sensitivity 79.2%, specificity 100%.
-
Genomic Concordance: 95–99% agreement with whole-genome sequencing in a 272-isolate subset.
-
WHO TPP: Met WHO minimum target product profile thresholds for isoniazid and rifampin.
4. Impact & Application
This assay offers labs a streamlined, near-patient option for rapidly detecting TB drug resistance. With perfect accuracyfor isoniazid and high accuracy for rifampin, it aligns with WHO standards and could significantly shorten time-to-diagnosis. The slightly lower sensitivity for some second-line drugs—especially capreomycin—highlights areas where further assay refinement could boost clinical utility.
5. Full Study Link
Read the full study here: 36757183
